Secreted Epithelial Stromal-1 Molecules and Uses Thereof

Abstract

The present invention provides novel Secreted Epithelial Colon Stromal-1 (Secs-1) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing Secs-1 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with Secs-1 polypeptides.

1 - 17 . (canceled) 
     
     
         18 . An antibody produced by immunizing an animal with a peptide comprising an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 5. 
     
     
         19 . An antibody or fragment thereof that specifically binds the polypeptide of  claim 18 . 
     
     
         20 . The antibody of  claim 19  that is a monoclonal antibody. 
     
     
         21 . A hybridoma that produces a monoclonal antibody that binds to a peptide comprising an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 5. 
     
     
         22 . A method of detecting or quantitating the amount of Secs-1 polypeptide using the anti-Secs-1 antibody or fragment of  claims 18 ,  19 , or  20 . 
     
     
         23 . A selective binding agent or fragment thereof that specifically binds at least one polypeptide wherein said polypeptide comprises the amino acid sequence selected from the group consisting of:
 (a) the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 5; and   (b) a fragment of the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 5;   
       or a naturally occurring variant thereof. 
     
     
         24 . The selective binding agent of  claim 23  that is an antibody or fragment thereof. 
     
     
         25 . The selective binding agent of  claim 23  that is a humanized antibody. 
     
     
         26 . The selective binding agent of  claim 23  that is a human antibody or fragment thereof. 
     
     
         27 . The selective binding agent of  claim 23  that is a polyclonal antibody or fragment thereof. 
     
     
         28 . The selective binding agent  claim 23  that is a monoclonal antibody or fragment thereof. 
     
     
         29 . The selective binding agent of  claim 23  that is a chimeric antibody or fragment thereof. 
     
     
         30 . The selective binding agent of  claim 23  that is a CDR-grafted antibody or fragment thereof. 
     
     
         31 . The selective binding agent of  claim 23  that is an antiidiotypic antibody or fragment thereof. 
     
     
         32 . The selective binding agent of  claim 23  which is a variable region fragment. 
     
     
         33 . (canceled) 
     
     
         34 . A selective binding agent or fragment thereof comprising at least one complementarity determining region with specificity for a polypeptide having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 5. 
     
     
         35 . The selective binding agent of  claim 23  which is bound to a detectable label. 
     
     
         36 - 59 . (canceled)